The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model

Anti-programmed death 1 (PD-1) is a revolutionary treatment for many cancers. The response to anti-PD-1 relies on several properties of tumor and immune cells, including the expression of PD-L1 and PD-1. Despite the impressive clinical benefit achieved with anti-PD-1 in several cancers in adults, th...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Delphine Sauvage, Manon Bosseler, Elodie Viry, Georgia Kanli, Anais Oudin, Guy Berchem, Olivier Keunen, Bassam Janji
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2022-09-01
Saila:	Cells
Gaiak:	neuroblastoma immune checkpoint inhibitors PD-1/PD-L1 immunotherapy hypoxia epigenetic drugs
Sarrera elektronikoa:	https://www.mdpi.com/2073-4409/11/18/2783
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!